Private company

Biostax Corp.

Biostax Corp. is an American pharmaceutical preparations company based in Orlando.²

Last updated Oct 21, 2026.

Overview

IndustryPharmaceutical Preparations²
HeadquartersOrlando, United States²
Incorporated inFL³
Business address2431 Aloma Ave #124, Winter Park, Fl 32792³
Filer categoryNon-accelerated filer, Smaller reporting company³
Legal formCorporation²
LEI549300H18XU575ZJKX93²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressC/O CORPORATE CREATIONS NETWORK, INC., 33408 Palm Beach, United States²
Registered withFlorida Division of Corporations, P93000082736²

See how the biggest companies compare on our leaderboards

Company’s growth forecast for the next three years is based on growing several internal and partner programs comprised of:⁴ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2018

58.0%Gross margin⁵

-3599.0%Operating margin⁵

-7599.7%Net margin⁵

-$1.4MFree cash flow⁵

Where the money goes

Where each dollar of revenue went, fiscal 2018

Selling, general and admin

Cost of revenue1¢$47.7K
Research and development4¢$144.1K
Selling, general and admin94¢$3.2M

Out of $113.5K in revenue.⁵ The company lost money this year.

Financial statements

Operating income⁶⁵-$4.1M in 2018−31% since 2017

Net income⁷⁵-$8.6M in 2018+9% since 2017

Fiscal year	2017	2018
Revenue		$113.5K⁵
Cost of revenue		$47.7K⁵
Gross profit		$65.8K⁵
Research and development	$399.4K⁶	$144.1K⁵
Selling, general and admin	$2.8M⁶	$3.2M⁵
Operating expenses
Operating income	-$5.9M⁶	-$4.1M⁵
Interest
Income tax
Net income	-$7.9M⁷	-$8.6M⁵
Earnings per share	-$0.02⁶	-$0.02⁶
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Total assets⁶⁵$91.6K in 2018−53% since 2017

Total liabilities⁶⁵$11.3M in 2018+0% since 2017

Shareholders’ equity⁵¹¹-$11.3M in 2018+1% since 2017

Cash⁶⁵$5.9K in 2018−60% since 2017

Fiscal year	2017	2018
Cash	$14.7K⁶	$5.9K⁵
Current assets	$192.8K⁶	$88.7K⁵
Total assets	$195.5K⁶	$91.6K⁵
Accounts payable
Current liabilities	$11.3M⁶	$11.3M⁵
Total liabilities	$11.3M⁶	$11.3M⁵
Retained earnings
Shareholders’ equity	-$11.1M⁵	-$11.3M¹¹
Shares outstanding	386.8M shares⁶	434.3K shares⁵

Cash from operations⁶⁵-$1.4M in 2018−33% since 2017

Capital spending⁶⁵$2.0K in 2018+31% since 2017

Free cash flow⁶⁵-$1.4M in 2018−33% since 2017

Fiscal year	2017	2018
Cash from operations	-$2.1M⁶	-$1.4M⁵
Stock-based compensation
Capital spending	$1.5K⁶	$2.0K⁵
Free cash flow	-$2.1M	-$1.4M
Cash from investing
Cash from financing

Compare Biostax Corp. with another company

Corporate structure

Biostax Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Biostax Corp.

Henry Louis Salomonsky Filed SC 13D on Biostax Corp., latest Dec 15, 2022

Biostax Corp. Orlando, Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Biostax Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$29.8K¹² Dec 31, 2023	$150.5K¹² Dec 31, 2022	−80.2%

Leadership

Who has led Biostax Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

Noreen Griffin2014–2016

President

Chief financial officer

Chief operating officer

201520202025

Chief executive officerNoreen Griffin Jun 23, 2014 to Jul 26, 2016¹³
PresidentSeth Elliott Jan 15, 2015 to Jan 15, 2015¹⁴
PresidentEugene Youkilis Jun 27, 2014 to Feb 12, 2015¹⁵
Chief financial officerGlen A. Farmer Dec 15, 2022 to Feb 22, 2023¹⁶
Chief financial officerPeter Aronstam Jul 1, 2014 to Jul 6, 2016¹⁷
Chief operating officerKelly O'Brien Wilson Dec 15, 2022 to Dec 15, 2022¹⁸
Chief operating officerSeth Elliott Jan 15, 2015 to Jan 15, 2015¹⁴
Chief operating officerChristopher Pearce Jun 24, 2014 to Jul 22, 2016¹⁹

Board members and other officers (10)

CHIEF SCIENCE OFFICERFengping Shan Jul 15, 2014 to Jul 15, 2014²⁰
Board memberHenry Louis Salomonsky Dec 15, 2022 to Dec 15, 2022²¹
Board memberEdward Teraskiewic Apr 7, 2016 to Apr 7, 2016²²
Board memberClifford Selsky Apr 8, 2016 to Apr 13, 2016²³
Board memberPaul Akin May 2, 2016 to Jul 6, 2016²⁴
Board memberVincent Butta Jan 15, 2015 to Jan 15, 2015²⁵
Board memberNoreen Griffin Jun 23, 2014 to Jul 26, 2016¹³
Board memberChristopher Pearce Jun 24, 2014 to Jul 22, 2016¹⁹
Board memberEugene Youkilis Jun 27, 2014 to Feb 12, 2015¹⁵
Board memberFengping Shan Jul 15, 2014 to Jul 15, 2014²⁰

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive OfficerCynthia Douglas named Aug 2, 2022 to Aug 31, 2022²⁶
Executive Officer, DirectorStephen Wilson named Aug 2, 2022 to Aug 31, 2022²⁶
DirectorKevin Phelps named Aug 2, 2022 to Aug 31, 2022²⁶
DirectorRobert Wilson named Aug 2, 2022 to Aug 31, 2022²⁶
DirectorRoscoe Moore named Aug 2, 2022 to Aug 31, 2022²⁶

Former names

Immune Therapeutics, Inc.Nov 14, 2014 to Sep 14, 2023³
TNI BIOTECH, INC.Oct 2, 2012 to Oct 30, 2014³

Timeline

Feb 20, 20258-K Listing notice or transfer; Regulation FD disclosure²⁷
Nov 14, 20238-K Executive or director change; Other events²⁸
Nov 2, 20238-K Executive or director change; Other events²⁹
Oct 24, 20238-K Bylaws or fiscal year changed; Other events³⁰
Sep 14, 20238-K Regulation FD disclosure³¹
Sep 13, 20238-K Executive or director change³²
Apr 20, 20238-K Entered a material agreement; Executive or director change; Other events³³
Mar 6, 20238-K Shareholder vote³⁴
Jan 3, 20238-K Executive or director change³⁵
Nov 9, 20228-K Entered a material agreement; Executive or director change; Other events³⁶
Oct 12, 20228-K Entered a material agreement³⁷
Sep 27, 20228-K Executive or director change; Other events³⁸
Jun 23, 2014New chief executive Noreen Griffin becomes CEO¹³
Dec 2, 1993Founded Biostax Corp. is founded²

Filings

52 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 16 major events, 5 insider forms, 1 large holders, 3 private raises, 12 other. The latest 20:

Jun 8, 202615-12G FORM 15 EDGAR
Jun 8, 2026D EDGAR
Apr 11, 202510-Q BIOSTAX CORP - FORM 10-Q SEC FILING EDGAR
Feb 20, 202525 EDGAR
Feb 20, 20258-K BIOSTAX CORP. - FORM 8-K SEC FILING EDGAR
Aug 19, 202410-Q EDGAR
Aug 19, 202410-Q/A EDGAR
Aug 14, 2024NT 10-Q EDGAR
Jul 5, 202410-K/A EDGAR
May 20, 202410-Q EDGAR
May 15, 2024NT 10-Q EDGAR
Apr 16, 202410-K EDGAR
Apr 1, 2024NT 10-K EDGAR
Nov 14, 20238-K EDGAR
Nov 14, 202310-Q EDGAR
Nov 2, 20238-K EDGAR
Oct 24, 20238-K EDGAR
Sep 14, 20238-K EDGAR
Sep 13, 20238-K EDGAR
Aug 18, 202310-Q EDGAR

The 52 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Feb 10, 2023	Farmer Glen AChief Financial Officer	Buy	409,000	$0.05	$20.4K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Henry Louis SalomonskySC 13D, 1 filing Dec 15, 2022³⁹

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$400.0K 2022–2022

Private raises (Form D) $400.0K

Figures by year

Year	Private raises (Form D)	Total
2022	$400.0K	$400.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

Dec 22, 2025Filed a private offering of equity⁴⁰ Form D: $7.5 million offered in all Form D
Aug 31, 2022Filed a private offering of debt²⁶ Form D: $5 million offered in all Form D
Jul 19, 2022Raised $400,000 in a private offering of securities⁴¹ Form D: 1 investor so far Form D

SEC filer profile

How Biostax Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARBiostax Corp.¹
CIK0001559356
Employer ID (EIN)59-3226705¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inFlorida¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address2431 Aloma Ave #124, Winter Park, FL 32792¹
Phone(888) 613-8802¹
Shares outstanding83,738,939 as of Aug 19, 2024¹⁰
Public float$11.0M as of Jun 30, 2023¹²
On EDGAR sinceOct 2, 2012¹
Filings320 in all: 8-K (87), 10-Q (36), 5 (34), 3 (27), UPLOAD (17), 4 (16), CORRESP (13), 10-K (11)¹
All 40 form types
10-12G/A (8), NT 10-Q (7), D (5), NT 10-K (5), 10-K/A (4), 8-K/A (4), SC 13G/A (4), DRSLTR (3), PRER14A (3), SC 13G (3), 10-Q/A (2), 5/A (2), CT ORDER (2), D/A (2), DEF 14A (2), DEFR14A (2), DRS/A (2), PRE 14A (2), PRER14C (2), S-1/A (2), SC 13D (2), 10-12G (1), 15-12G (1), 25 (1), 424B3 (1), DEF 14C (1), DEL AM (1), DRS (1), EFFECT (1), PRE 14C (1), S-1 (1), S-8 (1)
Latest filingsAnnual report (10-K) Apr 16, 2024
Quarterly report (10-Q) Apr 11, 2025
Proxy statement (DEF 14A) Apr 30, 2019
Latest 8-K (8-K) Feb 20, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARBiostax Corp. filings on SEC EDGAR
2
GLEIFBiostax Corp. LEI record (549300H18XU575ZJKX93)
3
SEC EDGARBiostax Corp. filings on SEC EDGAR
4
SEC EDGARBiostax Corp. annual report, Item 1 (Business)
5
SEC EDGARBiostax Corp. 10-K for fiscal 2018
6
SEC EDGARBiostax Corp. 10-K for fiscal 2017
7
SEC EDGARBiostax Corp. 10-K for fiscal 2017
8
SEC EDGARBiostax Corp. 10-Q for fiscal 2023
9
SEC EDGARBiostax Corp. 10-Q for fiscal 2024
10
SEC EDGARBiostax Corp. 10-Q for fiscal 2024
11
SEC EDGARBiostax Corp. 10-K for fiscal 2018
12
SEC EDGARBiostax Corp. 10-K/A for fiscal 2023
13
SEC EDGARNoreen Griffin, Chief executive officer
14
SEC EDGARSeth Elliott, President
15
SEC EDGAREugene Youkilis, President
16
SEC EDGARGlen A. Farmer, Chief financial officer
17
SEC EDGARPeter Aronstam, Chief financial officer
18
SEC EDGARKelly O'Brien Wilson, Chief operating officer
19
SEC EDGARChristopher Pearce, Chief operating officer
20
SEC EDGARFengping Shan, CHIEF SCIENCE OFFICER
21
SEC EDGARHenry Louis Salomonsky, Board member
22
SEC EDGAREdward Teraskiewic, Board member
23
SEC EDGARClifford Selsky, Board member
24
SEC EDGARPaul Akin, Board member
25
SEC EDGARVincent Butta, Board member
26
SEC EDGARBiostax Corp. Form D naming Cynthia Douglas
27
SEC EDGARListing notice or transfer; Regulation FD disclosure
28
SEC EDGARExecutive or director change; Other events
29
SEC EDGARExecutive or director change; Other events
30
SEC EDGARBylaws or fiscal year changed; Other events
31
SEC EDGARRegulation FD disclosure
32
SEC EDGARExecutive or director change
33
SEC EDGAREntered a material agreement; Executive or director change; Other events
34
SEC EDGARShareholder vote
35
SEC EDGARExecutive or director change
36
SEC EDGAREntered a material agreement; Executive or director change; Other events
37
SEC EDGAREntered a material agreement
38
SEC EDGARExecutive or director change; Other events
39
SEC EDGARHenry Louis Salomonsky SC 13D on Biostax Corp.
40
SEC EDGARForm D: Filed a private offering of equity
41
SEC EDGARForm D: Raised $400,000 in a private offering of securities